Deborah J Marsh

List of Publications by Year
in descending order

90 papers	4,026 citations	172457 29 h-index	118850 62 g-index
90 all docs	90 docs citations	90 times ranked	5501 citing authors

#	Article	IF	Citations
1	Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. Frontiers in Bioengineering and Biotechnology, 2022, 10, 836984.	4.1	22
2	The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics, 2022, 14, 837.	4.5	6
3	Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways. Cellular and Molecular Life Sciences, 2021, 78, 1011-1027.	5.4	10
4	Studying the Oncosuppressive Functions of PTENP1 as a ceRNA. Methods in Molecular Biology, 2021, 2324, 165-185.	0.9	1
5	Abstract 1062: Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibody. , 2021, , .		0
6	PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 8506.	4.1	8
7	Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. Molecular and Cellular Endocrinology, 2021, 533, 111338.	3.2	6
8	An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles. Journal of Materials Chemistry B, 2021, 9, 9123-9135.	5.8	11
9	Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer. Cancers, 2020, 12, 3462.	3.7	26
10	Toward Systems Pathology for PTEN Diagnostics. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037127.	6.2	4
11	The role of the free Î²-subunit of human chorionic gonadotropin in human malignancy. , 2020, , 269-281.		0
12	Writing Histone Monoubiquitination in Human Malignancyâ€"The Role of RING Finger E3 Ubiquitin Ligases. Genes, 2019, 10, 67.	2.4	35
13	Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. American Journal of Surgical Pathology, 2019, 43, 35-46.	3.7	74
14	Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecologic Oncology, 2018, 148, 181-188.	1.4	25
15	Histone H2B. , 2018, , 2384-2388.		0
16	CDC73. , 2018, , 991-995.		0
17	Abstract 3538: Targeting the E3 ubiquitin ligase RNF20 in ovarian cancer. , 2018, , .		0
18	Abstract A06: Cisplatin-induced DNA damage modifies the chromatin landscape of histone H2B monoubiquitination in a p53-dependent manner. , 2018, , .		0

#	Article	IF	Citations
19	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. Scientific Data, 2017, 4, 170120.	5.3	9
20	Lessons learnt from outstanding mid-career women in endocrine cancer research. Endocrine-Related Cancer, 2016, 23, E5-E7.	3.1	0
21	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 2016, 6, 26191.	3.3	162
22	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	2.9	26
23	Host-Guest Complexes of Carboxylated Pillar[n]arenes With Drugs. Journal of Pharmaceutical Sciences, 2016, 105, 3615-3625.	3.3	40
24	Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs. PLoS ONE, 2016, 11, e0153200.	2.5	160
25	Histone H2B. , 2016, , 1-5.		0
26	CDC73. , 2016, , 1-5.		0
27	Abstract B05: Assessment of TP53 mutation status in primary high-grade serous ovarian cancer and cell line models: Comparison between immunohistochemistry and next-generation sequencing.. , 2016, , .		0
28	Cowden Syndrome. , 2016, , 1218-1222.		0
29	Match that PhD. Nature, 2015, 523, 247-247.	27.8	2
30	Histone H2B monoubiquitination: roles to play in human malignancy. Endocrine-Related Cancer, 2015, 22, T19-T33.	3.1	108
31	Networks regulating ubiquitin and ubiquitin-like proteins promise new therapeutic targets. Endocrine-Related Cancer, 2015, 22, E1-E3.	3.1	1
32	A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer. Cancer Letters, 2015, 368, 64-70.	7.2	19
33	Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes and Cancer, 2015, 54, 1-19.	2.8	23
34	Abstract 1047: A role for the free beta subunit of human chorionic gonadotropin in sensitivity of epithelial ovarian cancer cells to platinum-based chemotherapeutics. , 2015, , .		0
35	Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Research, 2014, 16, R63.	5.0	90
36	Factors that May Influence the Willingness of Cancer Patients to Consent for Biobanking. Biopreservation and Biobanking, 2014, 12, 409-414.	1.0	10

#	Article	IF	Citations
37	Histones and Their Modifications in Ovarian Cancer Ã¢â‚¬â€œ Drivers of Disease and Therapeutic Targets. Frontiers in Oncology, 2014, 4, 144.	2.8	46
38	Cowden Syndrome. , 2014, , 1-6.		0
39	Tissue biomarkers of breast cancer and their association with conventional pathologic features. British Journal of Cancer, 2013, 108, 351-360.	6.4	27
40	Abstract A29: Loss of histone H2B monoubiquitination in ovarian cancer â€“ new therapeutic targeting opportunities based on chromatin relaxation. , 2013, , .		1
41	Abstract 330: Utilization of Sleeping Beauty mutagenesis for the identification of potential driver genes of ovarian cancer.. , 2013, , .		0
42	Abstract A10: A mutagenesis screen identifies tumor suppressors and kinases as potential driver genes of ovarian cancer. , 2013, , .		0
43	The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Human Molecular Genetics, 2012, 21, 559-568.	2.9	85
44	Hypercalcaemia due to parathyroid carcinoma presenting in the third trimester of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 204-207.	1.0	13
45	Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Letters, 2012, 317, 41-48.	7.2	11
46	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 2012, 12, 627.	2.6	163
47	Gonadotropin signalling in epithelial ovarian cancer. Cancer Letters, 2012, 324, 152-159.	7.2	50
48	Abstract 2167: The tumor suppressor CDC73/parafibromin is required for the maintenance of histone 2B monoubiquitination bothin vitroandin vivo. , 2012, , .		0
49	Abstract 3150: miR-100 in ovarian cancer cell lines. , 2012, , .		0
50	Multiple Endocrine Neoplasia: Types 1 and 2. Advances in Oto-Rhino-Laryngology, 2011, 70, 84-90.	1.6	14
51	Mutant AKT1 in Proteus Syndrome. New England Journal of Medicine, 2011, 365, 2141-2142.	27.0	10
52	Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy. Internal Medicine Journal, 2011, 41, 695-699.	0.8	6
53	Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells. Journal of Biological Chemistry, 2011, 286, 29540-29547.	3.4	18
54	Abstract 4962: Assessing serum miRNA as putative biomarkers for serous epithelial ovarian cancer. , 2011, , .		0

#	Article	IF	Citations
55	CDC73/HRPT2 CpG island hypermethylation and mutation of 5â€²-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	3.1	37
56	The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer, 2010, 17, 929-940.	3.1	98
57	Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase CÎ´. Endocrine-Related Cancer, 2010, 17, 335-349.	3.1	40
58	The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. Methods in Molecular Biology, 2010, 653, 133-145.	0.9	10
59	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	3.6	120
60	The effect of disease-associated HRPT2 mutations on splicing. Journal of Endocrinology, 2009, 201, 387-396.	2.6	10
61	Denaturing High Performance Liquid Chromatography Detection of SDHB, SDHD, and VHL Germline Mutations in Pheochromocytoma. Journal of Surgical Research, 2009, 157, 55-62.	1.6	20
62	Rapamycin treatment for a child with germline PTEN mutation. Nature Clinical Practice Oncology, 2008, 5, 357-361.	4.3	114
63	Cowden Syndrome. , 2008, , 759-762.		0
64	Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Letters, 2007, 581, 5070-5074.	2.8	44
65	Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 2007, 1, 377-392.	1.6	21
66	Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of Molecular Diagnostics, 2006, 8, 559-566.	2.8	16
67	Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 2006, 30, 1140-1149.	3.7	213
68	Genetic Testing in Pheochromocytoma- and Paraganglioma-Associated Syndromes. Annals of the New York Academy of Sciences, 2006, 1073, 104-111.	3.8	28
69	Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 827-836.	3.6	560
70	Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines. Cancer Research, 2006, 66, 1376-1383.	0.9	24
71	Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene, 2005, 24, 6241-6248.	5.9	65
72	A HIF1Î± Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	3.5	394

#	Article	IF	Citations
73	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.9	96
74	Diagnosis of Proteus syndrome was correct. American Journal of Medical Genetics Part A, 2004, 130A, 214-215.	2.4	8
75	A molecular diagnosis of hyperparathyroidismâ€"Jaw tumor syndrome in an adolescent with recurrent kidney stones. Journal of Pediatrics, 2004, 145, 567.	1.8	16
76	HRPT2 and parathyroid cancer. Lancet Oncology, The, 2004, 5, 78.	10.7	0
77	K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma. Clinical Endocrinology, 2004, 61, 510-514.	2.4	21
78	Von Hippelâ€"Lindau Disease. , 2004, , 1329-1333.		0
79	Cowden Syndrome. , 2004, , 301-304.		0
80	Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene, 2003, 22, 1358-1364.	5.9	108
81	Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults. American Journal of Human Genetics, 2003, 73, 1191-1198.	6.2	213
82	Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1866-1872.	3.6	54
83	A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 998-1001.	3.6	54
84	Comparative Genomic Hybridization Analysis of Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3467-3474.	3.6	125
85	Genetics of pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 79-86.	0.6	9
86	Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. American Journal of Pathology, 2002, 161, 1299-1306.	3.8	36
87	Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway. Gene, 2002, 298, 9-19.	2.2	17
88	Genetic insights into familial cancers â€" update and recent discoveries. Cancer Letters, 2002, 181, 125-164.	7.2	75
89	Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography. Neoplasia, 2001, 3, 236-244.	5.3	31
90	Mutational Analysis and Genotype-Phenotype Correlation of the PHEX Gene in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3889-3899.	3.6	27